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Effect of Glucagon and Methylprednisolone on Pancreatectomized 
Recipients of Whole Pancreas Allografts 
Luis H. Toledo-Pereyra, MD, PhD,* Michael Zammit, MD,* and Krishna D. Valjee, MD* 
Glucagon alone or in combination with methylpred-
nisolone was an adequate therapeutic adjuvant for pan-
createctomized recipients of whole pancreas allografts. All 
recipients were minimally immunosuppressed with 
azathioprine, 5.0 mg/K/day for three days, then 2.5 
mg/K/day. The morphological, functional, and survival 
response after whole pancreas transplantation indicated a 
trend of improvement in the treated groups. Only the groups 
of dogs receiving glucagon alone or in combination with 
methylprednisolone survived more than two weeks after 
transplantation. This therapy has proven to be effective for 
whole pancreas transplantation. 
Introduction 
M ANY attempts have been made to protect the pancreas 
from severe pancreatitis, edema, and hemorrhagic necrosis 
after transplantation.1 Tersigni and his group^'^ used meth-
ylprednisolone, glucagon, and allopurinol to protect pan-
creatico-duodenal allografts preserved by hypothermic 
pulsati le perfusion for twenty- four hours. Recently, 
Kyriakides and his colleagues""^ analyzed the beneficial 
effect of glucagon, trasylol, and steroids in duct-ligated, 
porcine pancreas transplants. We used mongrel dogs whose 
pancreatic ducts were not ligated. This work was designed to 
evaluate the effect of glucagon alone or in combination with 
methylprednisolone on the survival of pancreatectomized 
recipients of whole pancreas allografts. 
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Material and Methods 
Adult mongrel dogs of either sex, weighing between 15-25 
kg, were anesthetized with sodium thiamylal for induction 
and halothane (0.5-2.0%) for maintenance. Donor dogs 
received 500-750 ml of Ringer's lactate during the opera-
tion. Total pancreatectomy was performed according to 
Aquino's technique.'No warm ischemia was applied. A cuff 
of celiac trunk and portal vein was obtained forthe vascular 
anastomosis. After the organ was removed, it was flushed 
with cold (4°C) Ringer's lactate (200 ml) containing heparin 
(10,000 U/L), procaine (0.1 g/L), and methylprednisolone 
(250 mg/L) buffered with bicarbonate to a pH of 7.4. 
After total pancreatectomy, the pancreas from the donor 
animal was placed into the right iliac fossa with vascular 
continuity established between the host's right common 
iliac artery end-to-end to the celiac trunk and the donor's 
portal vein end-to-side to the inferior vena cava. The 
pancreatic duct was implanted using a technique modified 
from the one described by Aquino.' Almost all ofthe papilla 
was eliminated in order to leave the duct alone for the 
anastomosis wfth the jejunum or ileum. No blood transfu-
sions were given. The recipient dogs received approxi-
mately 750 ml of Ringer's lactate with dextrose 5% during 
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CAUSES OF DEATH OF ALL CANINE PANCREAS TRANSPLANTS' 
CAUSES GROUPS 
1 II III 
Pancreatitis 2 1 0 
Vascular thrombosis 1 0 0 
Intussusception 1 1 1 
Sepsis 1 1 1 
Pneumonia 0 1 1 
Pancreas rejection 2 2 2 
Cachexia 0 2 2 
Unknown 1 0 1 
TOTAL 8 8 8 
"This count excludes five dogs that died of unrelated or technical 
failures in the first three days posttransplantation. 
the operation and for six hours thereafter. Intravenous 
antibiotics were administered daily for one week, and oral 
alimentation was established in the third to fourth day. All 
dogs were minimally immunosuppressed with azathioprine, 
5 mg/K/day for three days, then 2.5 mg/K/day until death. 
Blood glucose and serum amylase tests were carried out 
daily for one week, then every third to fifth day until death. 
Autopsy was performed on all dogs with pancreas histologic 
examination. Statistical analysis was obtained with the 
method of analysis of variance in all data. 
Three groups of eight dogs each were studied. Group 1, the 
pancreas transplant control, received no treatment except 
for minimal immunosuppression. In Group II, donor dogs 
received glucagon (1 mg) infused intravenously in saline for 
over one hour, thirty minutes before and during pancreas 
excision, with atotal infusion rateof40 ju,g/k/h.Thereafter, 
the recipient animal received the same intravenous infusion 
duringtransplantation and 2 mg IM every six hours daily for 
three days. In Group 111, donor and recipient dogs were 
pretreated with 30 mg/K of methylprednisolone two hours 
before pancreatectomy in addition to receiving glucagon in 
the same dosages as the dogs in Group II. Thereafter, 500 mg 
IV were given duringtransplantation and 250mg IM twice a 
day for three days afterwards. 
Results 
Figure 1 shows the survival rates for all groups of dogs. The 
animals transplanted with pancreases treated wfth glucagon 
survived longer (p>0.08) than those in the untreated group. 
The addition of methylprednisolone to glucagon improved 
survival results even more when compared to the control 
group (p>0.01) or to the group treated with glucagon alone 
(p>0.1). 
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Fig.1 
Canine pancreas transplants treated wi th glucagon alone or in combina-
tion w i th methylprednisolone had better survival results than the un-
treated transplanted animals. 
The causes of death of all dogs included in this study are 
listed in the accompanying table. Five dogs that died of 
unrelated or technical failures in the first three days after 
transplantation were eliminated from this study. The causes 
of death were venous anastomotic bleeding (one dog from 
Group II), pancreatic duct leakage and peritonitis (two dogs 
from Group I, one dog from Group III), and anesthetic death 
(one dog from Group II). 
The blood glucose levels (Figure 2) were within normal 
limits in all groups of dogs for the first five days post-
transplantation. Thereafter, atone week after surgery, higher 
levels were observed in the control than in the treated 
groups (p>0.1->0.8). A continuous rise was observed from 
one week post-transplantation until death (Figure 2). 
The serum amylase levels (Figure 3) were normal in all 
groups only for the first two days post-transplantation. 
Thereafter, there was a steady and continuous increase, 
which was more dramatic at day 10 (Figure 3). Higher levels 
were observed in the control group than in the treated group 
of animals at days 7, 10, and 15 post-transplantation 
(p>0.08->0.1). No difference (p>0.5) was noted between 
the two groups of treated dogs at any t ime after 
transplantation. 
There were no significantdifferences (p>0.1->0.8) noted in 
the white blood cells between the three groups of animals. 
However, at one week post-transplantation higher levels 
were observed in the control group (24,050±1275 x mm) 
(M±SE) than in the treated groups (18,785 ±1067 x mm) 
(M±SE) (p>0.1). No significant changes (p>0.1->0.8) 
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Fig. 2 
Average blood glucose levels in all groups of animals. A delayed increase 
in blood glucose was observed in the treated groups. 
were observed in the hematocrit of all dogs after 
transplantation. 
Histologically, the pancreas of the control transplant dogs 
showed some duct dilatation, edema, lymphocytic infiltra-
tion, and architectural distortion (Figure 4). The groups 
treated wfth glucagon alone showed minimal ductdilatation 
and edema; cellular infiltration was not prominent, and 
architectural changes were moderate. The group treated 
with glucagon and methylprednisolone had no edema, and 
ductdilatation was occasionally seen. Cellular infiltration in 
this group was less significant than in Groups I and II. There 
were minimal to moderate architectural changes (Figure 5). 
Discussion 
This study confirms that glucagon alone or in combination 
with methylprednisolone is beneficial for canine pancreas 
transplantation. Morphological and functional response 
after transplantation, as well as the survival results, indicated 
improvement in the canine grafts treated with glucagon 
alone or combined with methylprednisolone. 
The mechanism of action of glucagon in improving pan-
creas transplant survival is not known. Glucagon has a 
definiteeffect in reducingexocrine pancreatic f u n c t i o n . I t 
affects the rate of flow, bicarbonate concentration, and rate 
of enzyme secretion by the pancreas with and without 
inflammation. It has been postulated that glucagon activates 
cycl ic 3 ' ,5 ' -AMP by increasing the act ivi ty of adenyl 
c y c l a s e . T h i s might also be an important factor. 
The most effective dosage of glucagon has not been worked 
out, and it is necessary to develop a good method to 
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Fig. 3 
Average serum amylase levels in all groups of animals. Lower values were 
observed in the treated groups than in the control. 
maximize its effect on pancreatic transplantation. Thirty 
minutes afterthe infusion has been administered glucagon 
practically disappears from the circulation. Its short-lasting 
eftect has to be considered for studies like this which are 
designed to protect pancreatic allografts for transplantation. 
Thirty to forty mg/K/hour appear to cause a significant 
inhibitory effect on pancreatic secretion.""^' However, 
Kyriakides and his associates^ demonstrated that 2 mg of 
glucagon administered IM daily were effective for auto-
grafts, but had no beneficial effect on allografts. Increasing 
the dose to 4 mg twice a day was also ineffective in 
prevenfing pancreatic fluid accumulation, although it ap-
peared to prevent hyperamylasemia.'' When the same total 
dose was administered more frequently (2 mg IM every six 
hours), significant decrease in fluid accumulation around 
the pancreas was observed. From the work of Kyriakides etal 
and from other studies, it appears that a dosage of 2 mg IM 
every six hours is the most adequate way to treat pancreatic 
allografts at the present time. 
The beneficial effect of steroids on pancreas allografts is 
probably due to the anti-inflammatory^'"^^ and membrane 
stabilizing properties ofthese s u b s t a n c e s . I n addition, it 
is possible that their immunosuppressive effect could be an 
important factor in the prolongation of survival. Although 
there is some evidence in the literature that steroids can 
cause pancreatitis,"'" in our work and others""^-^"-^^ their 
beneficial effect has been well established. The question is 
not whether steroids are beneficial, but mainly what is their 
most effecfive use in terms of dosage and timing. 
In summary, canine pancreas allografts survived an average 
of 11.6 days when no treatment was given except minimal 
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Fig. 4 
Histological appearance of an untreated pancreas several days posttransplantation (X325). Note architectural 
distortion and poor preservation of acini and islets. 
Fig. 5 
Histological appearance of pancreas treated wi th glucagon and methylprednisolone several days posttransplantation 
(X325). Good preservation of islets and acini is observed. 
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immunosuppression. The administration of glucagon pro-
longed survival to an average of 16.8 days. The combination 
of glucagon and methylprednisolone was even more effec-
tive, improving pancreas allograft survival to an average of 
19.5 days. Thus, ft is evident that glucagon alone or in 
combinat ion w i th methylprednisolone is an adequate 
therapeutic adjuvant for canine pancreas allografts. 
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